Advertisement

pp 1-8 | Cite as

Clostridium difficile Colitis Prevention and Treatment

  • Meltem Dinleyici
  • Yvan VandenplasEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series

Abstract

Clostridium difficile (C. diff) is the most common causative agent of antibiotic-associated diarrhea and colitis. This spore-forming, obligate anaerobic, gram-positive bacillus is becoming responsible for an increasing number of infections worldwide, both in community and in hospital settings, whose severity can vary widely from an asymptomatic infection to a lethal disease. While discontinuation of antimicrobial agents and antibiotic treatment of the infection remain the cornerstone of therapy, the use of probiotics, especially Saccharomyces boulardii, and more recently of fecal microbiota transplantation have become valid forms of prevention and/or therapy and are here critically examined.

Keywords

Antibiotic associated diarrhea Clostridium difficile Colitis 

References

  1. Adams DJ, Eberly MD, Rajnik M et al (2017) Risk factors for community-associated clostridium difficile infection in children. J Pediatr 186:105–109Google Scholar
  2. Ambalam P, Kondepudi KK, Balusupati P et al (2015) Prebiotic preferences of human lactobacilli strains in co-culture with bifidobacteria and antimicrobial activity against clostridium difficile. J Appl Microbiol 119:1672–1682Google Scholar
  3. Buts JP, Corthier G, Delmee M (1993) Saccharomyces boulardii for Clostridium difficile – associated enteropathies in infants. J Pediatr Gastroenterol Nutr 16:419–425Google Scholar
  4. Buts JP, De Keyser N, Marandi S et al (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45:89–96Google Scholar
  5. Cameron D, Hock QS, Kadim M et al (2017) Probiotics for gastrointestinal disorders: proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol 23:7952–7964Google Scholar
  6. Cammarota G, Ianiro G, Gasbarrini A (2014) Fecal microbiota transplantation for the treatment of clostridium difficile infection: a systematic review. J Clin Gastroenterol 48:693–702Google Scholar
  7. Castagliuolo I, Riegler MF, Valenick L et al (1999) Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 67:302–307Google Scholar
  8. Chen X, Kokkotou EG, Mustafa N et al (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against clostridium difficile toxin A-induced enteritis. J Biol Chem 281:24449–24454Google Scholar
  9. Crow JR, Davis SL, Chaykosky DM et al (2015) Probiotics and fecal microbiota transplant for primary and secondary prevention of clostridium difficile infection. Pharmacotherapy 35:1016–1025Google Scholar
  10. D’Ostroph AR, So TY (2017) Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value. Infect Drug Resist 10:365–375Google Scholar
  11. Davidovics ZH, Michail S, Nicholson MR et al (2018) FMT special interest group of the North American society of pediatric gastroenterology hepatology and nutrition and the European society for pediatric gastroenterology hepatology and nutrition. Fecal microbiota transplantation for recurrent Clostridium difficile infection and other potential applications in children: clinical report. J Pediatr Gastroenertol Nutr. submittedGoogle Scholar
  12. Drekonja D, Reich J, Gezahegn S et al (2015) Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 162:630–638Google Scholar
  13. El-Hawiet A, Kitova EN, Kitov PI et al (2011) Binding of clostridium difficile toxins to human milk oligosaccharides. Glycobiology 21:1217–1227Google Scholar
  14. El-Hawiet A, Kitova EN, Klassen JS (2015) Recognition of human milk oligosaccharides by bacterial exotoxins. Glycobiology 25:845–854Google Scholar
  15. Elmer GW, McFarland LV, Surawicz CM et al (1999) Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Almin Pharmacol Ther 13:1663–1668Google Scholar
  16. Faden HS, Ma CX (2016) Trends in oral antibiotic, proton pump inhibitor, and Histamine 2 Receptor Blocker prescription patterns for children compared with adults: implications for Clostridium difficile infection in the community. Clin Pediatr (Phila) 55:712–716Google Scholar
  17. Flatley EA, Wilde AM, Nailor MD (2015) Saccharomyces boulardii for the prevention of hospital onset clostridium difficile infection. J Gastrointestin Liver Dis 24:21–24Google Scholar
  18. Esposito S, Umbrello G, Castellazzi L et al (2015) Treatment of clostridium difficile infection in pediatric patients. Expert Rev Gastroenterol Hepatol 9:747–755Google Scholar
  19. Gerding DN, Johnson S (2010) Management of clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 51:1306–1313Google Scholar
  20. Gibson MK, Crofts TL, Dantas G (2015) Antibiotics and the developing infant gut microbiota and resistome. Curr Opin Microbio 27:51–56Google Scholar
  21. Goldenberg JZ, Ma SS, Saxton JD et al (2013) Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 5:CD006095Google Scholar
  22. Goldenberg JZ, Lytvyn L, Steurich J et al (2015) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst 22:CD004827Google Scholar
  23. Goldenberg JZ, Mertz D, Johnston BC (2018) Probiotics to prevent clostridium difficile infection in patients receiving antibiotics. JAMA. (in press 320:499Google Scholar
  24. Goldstein EJ, Tyrrel KL, Citron DM (2015) Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 60(Suppl 2):98–107Google Scholar
  25. Ianiro G, Valerio L, Masucci L et al (2017) Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect 23:337.e1–337.e3Google Scholar
  26. Johnston BC, Ma SS, Goldenberg JZ et al (2012) Probiotics for the prevention of clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157:878–888Google Scholar
  27. Johnston BC, Goldenberg JZ, Parkin PC (2016) Probiotics and the prevention of antibiotic-associated diarrhea in infants and children. JAMA 316:1484–1485Google Scholar
  28. Johnston BC, Lytvyn L, Lo CK et al (2018) Microbial preparations (Probiotics) for the prevention of clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants. Infect Control Hosp Epidemiol 39:771–781Google Scholar
  29. Kassam Z, Lee CH, Yuan Y, Hunt RH (2013) Fecal microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108:500–508Google Scholar
  30. Koon HW, Su B, Xu C et al (2016) Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated clostridium difficile-associated cecal inflammation in hamsters. Am J Physiol Gastrointest Liver Physiol 311:G610–G623Google Scholar
  31. Lau CS, Chamberlain RS (2016) Probiotics are effective at preventing clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med 9:27–37Google Scholar
  32. Li N, Zheng B, Cai HF et al (2018) Cost-effectiveness analysis of oral probiotics for the prevention of clostridium difficile-associated diarrhoea in children and adolescents. J Hosp Infect 99:469–474Google Scholar
  33. Mantegazza C, Molinari P, D’Auria E et al (2018) Probiotics and antibiotic-associated diarrhea in children: a review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res 128:63–72Google Scholar
  34. McFarland LV, Surawicz CM, Greenberg RN et al (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913–1918Google Scholar
  35. McFarland LV, Ozen M, Dinleyici EC et al (2016) Comparison of pediatric and adult antibiotic-associated diarrhea and clostridium difficile infections. World J Gastroenterol 22:3078–3104Google Scholar
  36. McKonnie R, Kasti A (2017) Clostridium difficile, colitis, and colonoscopy: pediatric perspective. Curr Gastroenterol Rep 19:34Google Scholar
  37. Nguyen TT, Kim JW, Park JS (2016) Identification of oligosaccharides in human milk bound onto the toxin A carbohydrate binding site of Clostridium difficile. J Microbiol Biotechnol 26:659–665Google Scholar
  38. Nylund CM, Eide M, Gorman GH (2014) Association of clostridium difficile infections with acid suppression medications in children. J Pediatr 165:979–984.e1Google Scholar
  39. Ooi CY, Dilley AV, Day AS (2009) Saccharomyces boulardii in a child with recurrent Clostridium difficile. Pediatr Int 51:156–158Google Scholar
  40. Pant C, Deshpande A, Altaf MA et al (2013) Clostridium difficile infection in children: a comprehensive review. Curr Med Res Opin 29:967–984Google Scholar
  41. Sammons JS, Toltzis P, Zaoutis TE (2013) Clostridium difficile infection in children. JAMA Pediatr 167:567–573Google Scholar
  42. Shen NT, Leff JA, Schneider Y et al (2017a) Cost-effectiveness analysis of probiotic use to prevent clostridium difficile infection in hospitalized adults receiving antibiotics. Open Forum Infect Dis 4:ofx148Google Scholar
  43. Shen NT, Maw A, Tmanova LL et al (2017b) Timely use of probiotics in hospitalized adults prevents clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152:1889–1900.e9Google Scholar
  44. Schutze GE, Willoughby RE, Committee on Infectious Diseases; American Academy of Pediatrics (2013) Clostridium difficile infection in infants and children. Pediatrics 131:196–200Google Scholar
  45. Sinclair A, Xie X, Saab L et al (2016) Lactobacillus probiotics in the prevention of diarrhea associated with Clostridium difficile: a systematic review and Bayesian hierarchical meta-analysis. CMAJ Open 4:E706–E718Google Scholar
  46. Spigaglia P, Barbanti F, Castagnola E et al (2017) Clostridium difficile causing pediatric infections: new findings from a hospital-based study in Italy. Anaerobe 48:262–268Google Scholar
  47. Surawicz CM, McFarland LV, Elmer G et al (1989b) Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84:1285–1287Google Scholar
  48. Surawicz CM, Elmer GW, Speelman P et al (1989a) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96:981–988Google Scholar
  49. Surawicz CM, McFarland LV, Greenberg RN et al (2000) The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31:1012–1017Google Scholar
  50. Szajewska H, Canani RB, Guarino A et al (2016) ESPGHAN working group for probiotics & prebiotics. Probiotics for the prevention of antibiotic-associated diarrhea in Children. J Pediatr Gastroenterol Nutr 62:495–506Google Scholar
  51. Tannock GW, Munro K, Taylor C et al (2010) A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of clostridium difficile-infected patients than does vancomycin. Microbiology 156.(Pt 11:3354–3359Google Scholar
  52. Turck D, Bernet JP, Marx J et al (2003) Incidence and risk factors of oral antibiotic associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37:22–26Google Scholar
  53. Valdés-Varela L, Gueimonde M, Ruas-Madiedo P (2018) Probiotics for prevention and treatment of clostridium difficile infection. Adv Exp Med Bio 1050:161–176Google Scholar
  54. Vermeersch SJ, Vandenplas Y, Tanghe A et al (2018) Economic evaluation of S boulardii CNCM I-745 for prevention of antibiotic-associated diarrhoea in hospitalized patients. Acta Gastro-Enterol Belg 81:269–276Google Scholar
  55. Vernaya M, McAdam J, Hampton MD (2017) Effectiveness of probiotics in reducing the incidence of clostridium difficile-associated diarrhea in elderly patients: a systematic review. JBI Database System Rev Implement Rep 15:140–164Google Scholar
  56. Wei L, Ratnayake L, Phillips G et al (2017) Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. Br J Clin Pharmacol 83:1298–1308Google Scholar
  57. Yi SH, Jernigan JA, McDonald LC (2016) Prevalence of probiotic use among inpatients: a descriptive study of 145 U.S. hospitals. Am J Infect Contro 44:548–553Google Scholar
  58. Zar FA, Bakkanagari SR, Moorthi KM et al (2007) A comparison of vancomycin and metronidazole for the treatment of clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Eskisehir Osmangazi University Faculty of Medicine, Department of Social PediatricsEskisehirTurkey
  2. 2.KidZ Health Castle, UZ Brussel, Vrije Universiteit BrusselBrusselsBelgium

Personalised recommendations